St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
Also called: gangliocytoma, ganglioneuroma
Ganglioglioma is a type of low-grade glioma. Pediatric low-grade gliomas are the most common central nervous system (CNS) tumors in children. They make up 30% of all childhood CNS tumors.
Studies have shown that almost all low-grade gliomas have certain molecular mutations, or errors, that occur in the tumor cells. For the most part, these mutations can be targeted with new specialized medicines called targeted therapies. This means that molecular testing must occur on the tumor to get the correct diagnosis and determine the best treatment.
Most gangliogliomas occur in children and young adults. These are slow-growing tumors of the brain or spine. These tumors may affect the function of the brain or the body, depending on where they are located.
Find out more about ganglioglioma on the Together by St. Jude™ online resource.
The medical team is often made up of an oncologist, surgeon, and radiation oncologist, along with nurses and other care staff. They will discuss the types of treatment and help you decide on the best option for your child. The most common treatments are surgery, targeted therapy, chemotherapy, and radiation therapy.
St. Jude clinical trials have produced new, groundbreaking treatments for serious childhood diseases. Our doctors and scientists work together to find better ways to treat patients. In many cases, new treatments are being developed right here on the St. Jude campus.
We also take part in trials developed by the Children’s Oncology Group (COG) and the Pediatric Brain Tumor Consortium (PBTC). Many St. Jude staff members play key roles in developing these studies. They are large studies carried out at centers across the United States.
Study goal:
The main purpose of this study is to find out what happens, good and bad, to memory and learning when the hippocampus is avoided during proton therapy radiation.
Age:
At least 6 years old and younger than 22
Study goal:
The main goal of this study is to test the experimental drug mirdametinib in hopes of finding a treatment that may be effective against low-grade glioma brain tumors in children, adolescents and young adults.
Age:
At least 2 years old and younger than 25 years old.
St. Jude provides the highest quality of care for patients with ganglioglioma:
More reasons to choose St. Jude for care include:
Get more information about the Brain Tumor Treatment program at St. Jude.
Patients accepted to St. Jude must have a disease we treat and must be referred by a physician or other qualified medical professional. We accept most patients based on their ability to enroll in an open clinical trial.
You can start the referral process by letting your doctor know you would like a second opinion from St. Jude. They can contact our 24-hour beeper service or contact our brain tumor coordinator. You may also contact the brain tumor coordinator directly with questions.
Learn more about the types of brain tumors we treat at St. Jude and our brain tumor eligibility requirements.
Call: 1-888-226-4343 (toll-free) or 901-595-4055 (local) | Email: referralinfo@stjude.org
Fax: 901-595-4011 | 24-hour pager: 1-800-349-4334
Contact the Brain Tumor Team directly:
Contact the Surgery Team directly: